Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 18/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7141533 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4611907 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4613697 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4612949 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4613981 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4614280 | 0.81 | PTGS2 (0.81) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4612116 | 0.80 | PTGS2 (0.74) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4612538 | 0.80 | PTGS2 (0.77) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4611762 | 0.79 | PTGS2 (0.83) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4612105 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-2023718-A2 | CREATINE-LIGAND COMPOUNDS AND METHODS OF USE THEREOF | Avicena Group, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2008137137-A1 | CREATINE ASCORBYL DERIVATIVES AND METHODS OF USE THEREOF | AVICENA GROUP, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| EP-1938803-A2 | Formulations comprising nanoparticulate meloxican | Elan Pharma International Limited (IE) | 2008-07-02 | — | — | EP | claimed |
| WO-2007133731-A2 | CREATINE-LIGAND COMPOUNDS AND METHODS OF USE THEREOF | AVICENA GROUP, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20060093687-A1 | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain | BOUNTRA CHARANJIT | 2006-05-04 | — | — | US | claimed |
| EP-1617816-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | Elan Pharma International Limited (IE) | 2006-01-25 | — | — | EP | claimed |
| EP-1572237-A1 | COMBINATIONS OF VANILLOID ANTAGONIST AND NSAID FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2005-09-14 | — | — | EP | claimed |
| WO-2005002542-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-01-13 | — | — | WO | claimed |
| US-20040229038-A1 | Nanoparticulate meloxicam formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-11-18 | — | — | US | claimed |
| WO-2004056394-A1 | COMBINATIONS OF A VANILLOID ANTAGONIST AND AN NSAID FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| EP-1239879-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND COX2-INHIBITORS | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | claimed |
| US-20030004128-A1 | Formulatios of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | claimed |
| EP-1239879-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | claimed |
| WO-2001045683-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735446-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-5656661-A | ANALGESICS | THE PROCTER & GAMBLE COMPANY (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0773939-A1 | DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003396-A1 | DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093687-A1 | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain | TRPV1, TRPV2, TRPV3 | PTGS2 129/4885PTGS1 59/4885ALOX5 455/4885 |
| US-20030004128-A1 | Formulatios of adenosine a1 agonists | ADORA1, ADORA2A, ADORA2B | PTGS2 25/4885PTGS1 20/4885ALOX5 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.